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Tumor suppressors BTG1 and BTG2 regulate early
mouse B-cell development 
Transcription factors that regulate B-cell differentiation
are frequently targeted by genetic aberrations in B-cell
malignancies. The B-cell translocation gene 1 (BTG1),
which encodes a transcription coregulator,1,2 is recurrent-
ly affected by gene deletions in B-cell precursor acute
lymphoblastic leukemia (BCP-ALL),3-5 and targeted by
missense mutations in diffuse large B-cell lymphomas
(DLBCL).6,7 Similarly, the closely related BTG2 gene is
subject to mutations in DLBCL, Burkitt lymphoma and
follicular lymphoma.6-9 To establish the role of BTG1 and
BTG2 in B lymphopoiesis, we studied the composition of
the hematopoietic compartment in mice deficient for
either Btg1 or Btg2, as well as in Btg1;Btg2-double knock-
out animals. We found that Btg1 and Btg2 are both
required at multiple stages of early B-cell development,
but also display specific functions in progenitor B-cells.
Our data demonstrate that transcriptional cofactors
BTG1 and BTG2 act as important regulators of B-cell dif-
ferentiation, providing an important link to their role as
tumor suppressors in B-cell malignancies.   
To determine the function of Btg1 and Btg2 during nor-
mal hematopoiesis we performed flow cytometric analy-
sis of the bone marrow (BM) compartment and spleen.
The fraction of B220+ progenitor B-cells was significantly
reduced in Btg1- and Btg2-deficient mice, ranging from a
10% decrease in the Btg2–/– mice, 20% in Btg1–/– mice, to
40% in the Btg1–/–;Btg2–/– double knockout animals relative
to control mice (Figure 1A). Similarly, B-cell counts in the
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Figure 1. Decreased B-cell numbers in mice deficient for
Btg1 and Btg2. (A-B) Flow cytometric analysis was performed
on mononuclear cells isolated from bone marrow (BM) and
spleen of wild-type (WT) control (n=16), Btg1–/– (n=7), Btg2–/–
(n=8) and Btg1–/–;Btg2–/– mice (n=11). The fractions of
B220+ BM cells (A) and B220+IgM+ splenocytes (B) are indi-
cated. Each dot represents an individual sample and the hor-
izontal line indicates the mean. (C) Competitive repopulation
assay of wild-type and Btg1–/–;Btg2–/– donor cells (CD45.2)
derived of BM mixed 1:1 with CD45.1 wild-type cells which
were transplanted into 9Gy (Gray) irradiated C57BL6/J mice
(CD45.1). Flow cytometric analysis was performed on blood
and spleen. The fraction of B220, CD3 and Mac-1 of WT:WT
(CD45.1:CD45.1) (n=4) and WT:Btg1–/–;Btg2–/–
(CD45.1:CD45.2) (n=6) cells are indicated. (D) Schematic
representation of the different B-cell developmental stages
according to Hardy nomenclature. Cell surface markers that
distinguish specific Hardy fractions are indicated. (E) The
percentage for the different Hardy B-cell fractions within BM
is indicated as determined in WT control (n=16 ), Btg1–/–
(n=7), Btg2-/- (n=8), and Btg1–/–;Btg2–/– (n=11) mice. Each
bar represents the mean of each group of mice ± the stan-
dard error of the mean (SEM). *P<0.05, **P<0.01,
***P<0.001.
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spleen were most significantly reduced in Btg1–/–; Btg2–/–
mice, with about 30% fewer B220+IgM+ B-cells (Figure
1B). In contrast, the fraction of myeloid progenitor cells
in BM was not altered in the Btg1- and Btg2-deficient ani-
mals (Online Supplementary Figure S1). In addition, we did
not observe any specific defects in T-cell development in
mice lacking Btg1 and Btg2 expression (Online
Supplementary Figure S2).
To assess whether the defect in B lymphopoiesis was
not related to defective support from the BM microenvi-
ronment in the Btg1 and Btg2 knockout animals, compet-
itive repopulation assays were performed. BM cells
derived from either wild-type (CD45.2) or Btg1–/–;Btg2–/–
mice (CD45.2) were mixed with competitor wild-type
cells (CD45.1) and transplanted into lethally irradiated
C57BL6/J mice (CD45.1). FACS analysis on peripheral
blood and spleen demonstrated that contribution to the
B-cell lineage was significantly reduced using
Btg1–/–;Btg2–/– donor cells when compared to wild-type
donor cells (Figure 1C), arguing that the observed defect
in B-cell development is cell autonomous.
To establish at what stage of early B-cell development
Btg1- and Btg2-deficiency affect B-cell differentiation, we
investigated the relative frequencies of the different B-cell
subsets within the BM compartment. Analysis of the
common lymphoid progenitor (CLP) fraction, defined as
lineage negative (Lin–) Sca-1+c-Kit+Flt3+Il-7Rα+ cells,
revealed no significant differences in Btg1–/–, Btg2–/– and
Btg1–/–;Btg2–/–mice compared to wild-type controls (Online
Supplementary Figure S3). Next, we employed the cell sur-
face markers B220, CD43, CD24, IgD and IgM, to distin-
guish different B-cell precursor populations, generally
known as Hardy fractions (Figure 1D). When we exam-
ined the single knockout animals, the Btg2–/– mice dis-
played decreased B-cell fractions at both the early and
later stages of B-cell differentiation, while Btg1-deficiency
resulted only in reduced B-cell fractions beyond the pre-
B cell stage, including the immature B-cells (Hardy frac-
tions E and F) (Figure 1E). In the Btg1–/–;Btg2–/– mice, we
observed a similar phenotype as the Btg2–/– mice at the
early stages of B-lineage differentiation, with a moderate
decrease in the pool of pro-B cells (Hardy BC) compared
to control mice. However, from the pre-B cell stage
onwards, the Btg1–/–;Btg2–/– mice displayed a more pro-
nounced phenotype in comparison to the Btg1–/– and
Btg2–/– single knockout animals, showing a 2-fold reduc-
tion in the B220+CD43– cell fraction relative to control
mice (Hardy D, E and F) (Online Supplementary Figure S4).
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Figure 2. Btg1 stimulates B-cell progenitor
outgrowth in response to IL-7. (A) Bone marrow
(BM) mononuclear cells (1 x 105 cells) were
isolated from wild-type (WT) control (n=18),
Btg1–/– (n=7), Btg2–/– (n=8) and Btg1–/–;Btg2–/–
mice (n=11) and added in methylcellulose con-
taining 10 ng/mL IL-7. (B) BM mononuclear
cells were isolated from WT control (n=10),
Btg1–/– (n=7), Btg2–/– (n=4) and Btg1–/–;Btg2–/–
mice (n=4) and added after CD19 isolation (2
x 104 CD19+ cells) in methylcellulose contain-
ing 10ng/ml IL-7. (A, B) Mean colony counts
(and SEM) were determined (>30 cells/colony)
after seven days of culture. Data are represen-
tative of at least two independent experiments.
**P<0.01, ***P<0.001. (C) BM cells from WT,
Btg1–/–, Btg2–/–, and Btg1–/–;Btg2–/– mice (all
n=2) were stained with B220 and IL-
7Rα/CD127 antibodies and the percentage of
IL-7Rα-positive cells within the B220+ fraction
was determined. The black line indicates IL-
7Rα expression in the WT cells, while the blue
peak shows the IL-7Rα expression in the
Btg1–/–, Btg2–/– and Btg1–/–;Btg2–/– double
knockout cells. (D) Apoptosis assay of CD19+
BM cells isolated from WT (n= 4) and Btg1–/–
(n=7) cultured for 4 days in B-cell specific
medium, by measuring Annexin V using flow
cytometry. The percentage of Annexin V-posi-
tive cells in CD19+ BM cells is indicated. (E)
Proliferation assay of CD19+ BM cells isolated
from WT (n= 3) and Btg1–/– (n=3) cultured for 4
days in B-cell specific medium, measuring Ki-
67 by flow cytometry. The cell cycle distribution
according to Ki-67 staining in CD19+ BM cells
is indicated. Each bar represents the mean of
each group of mice ± the standard error of the
mean (SEM). **P<0.01, ***P<0.001.   
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We conclude from these results that Btg1 and Btg2 are
both required for mouse B-cell development, while defi-
ciency for each of the genes shows a different outcome
on the relative abundance of the specific Hardy fractions.  
To more specifically assess the function of Btg1 and
Btg2 in early B lymphopoiesis, we investigated whether
interleukin-7 (IL-7) dependent outgrowth of  B-lymphoid
progenitor cells was affected in the absence of Btg1 and
Btg2 expression. BM cells derived from Btg1–/–, Btg2–/– sin-
gle knockout and Btg1–/–;Btg2–/– double knockout mice
were plated in methylcellulose and cultured for one week
in the presence of cytokine IL-7. The number of colonies
in methylcellulose was about 4-fold lower in cultures
derived from Btg1–/– and Btg1–/–;Btg2–/– BM cells relative to
those derived from control BM cells (Figure 2A).
Moreover,  colony size was also reduced in these two
knockout genotypes (data not shown). In contrast, 
Btg2-deficiency had no significant impact on the out-
growth of lymphoid progenitor cells in the IL-7-depen-
dent methylcellulose colony formation assay. Given the
fact that the number of B220+ B-cell progenitors was
decreased in the BM of the different Btg1 and Btg2 knock-
out lines, we also analyzed the colony outgrowth of sim-
ilar amounts of purified CD19+ progenitor B-cells under
the same conditions. Again, colony formation was signif-
icantly impaired using CD19+ cells derived from Btg1–/–
and Btg1–/–;Btg2–/– mice, but not with Btg2–/– progenitor 
B-cells, which indicates that the loss of Btg1 function is
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Figure 3. Aberrant T-lineage gene expression in progenitor B-cells deficient for Btg1 and Btg2. (A) Relative expression levels of B-cell transcription factors E2A
(Tcf3), Foxo1, Ebf1 and Pax5 was determined using cDNA generated from B220+ bone marrow (BM) cells of wild type control (WT), Btg1–/–, Btg2–/– and
Btg1–/–;Btg2–/–mice by qRT-PCR and normalized to the expression of the housekeeping gene TBP. (B) RNA was isolated from B220+CD43+ and B220+CD43– cells
derived from wild type control and Btg1–/–;Btg2–/– mice (n=4) and analyzed by microarray using the Illumina BeadArray platform. The data obtained were RMA
normalized and relative gene expression differences of >1.6-fold was determined. KEGG pathway analysis was performed using the online Gene Set Enrichment
Analysis (GSEA) tool and relevant pathways with highest P-value that are differentially expressed between WT and Btg1–/–;Btg2–/– cells are indicated. (C) Relative
expression levels of Cd4, Ikzf2, Tcf7, Gata3 and Notch1 were determined on cDNA generated from B220+ BM cells of the different genotypes by real-time PCR
and normalized to TBP expression. (A and C) Data represent the mean and SEM  of three independent experiments containing cDNA derived from 2 different
biological samples. *P<0.05, **P<0.01, ***P<0.001.
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Gene set enrichment analysis of Btg1–/–;Btg2–/– vs. WT
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largely responsible for the defective outgrowth of B-lym-
phoid progenitors (Figure 2B). 
To assess whether differences in colony formation
could be attributed to reduced expression levels of the IL-
7 receptor alpha (IL-7Rα/CD127), CD127 expression was
measured on B220+ BM cells by flow cytometry. We
observed that IL-7Rα expression was not decreased in
Btg1–/– progenitor B-cells, but was even upregulated in
Btg1–/–;Btg2–/– cells (Figure 2C), arguing that the low num-
ber of colonies due to Btg1-deficiency was not related to
reduced IL-7Rα expression levels. Next, we examined
whether Btg1-deficient CD19+ cells displayed intrinsic
differences in the level of apoptosis and proliferation. We
observed a moderate but significant increase in the frac-
tion of Annexin V-positive cells derived from Btg1–/– mice
(Figure 2D; Online Supplementary Figure S5), while the cell
cycle distribution, as determined by Ki-67 staining, was
not affected (Figure 2E). Thus, Btg1 appears to be
required for optimal IL-7 dependent B-lymphoid colony
formation, in part by promoting cell survival in early pro-
genitor B-cells.
To elucidate how Btg1 and Btg2 regulate B-cell develop-
ment in vivo, we examined the expression of key tran-
scription factors involved in early B-cell differentiation,
including E2a (Tcf3), Foxo1, Ebf1, and Pax5.10,11
Quantitative reverse transcription polymerase reaction
(qRT-PCR) on RNA isolated from B220+ sorted BM cells
of Btg1–/–, Btg2–/– and Btg1–/–;Btg2–/– mice demonstrated that
the expression of these master regulators of B-cell differ-
entiation was not decreased (Figure 3A). On the contrary,
mRNA expression levels of these transcription factors
were even somewhat elevated in the absence of Btg1 and
Btg2. Hence, the partial block in B-cell differentiation
observed in the Btg1–/–;Btg2–/– animals cannot be explained
by diminished expression levels of these B-lineage tran-
scription factors. 
Next, we performed microarray based gene expression
profiling using early (B220+CD43+) and late progenitor 
B-cells (B220+CD43-) isolated from control and Btg1–/–;
Btg2–/– mice and performed Gene Set Enrichment
Analyses (GSEA) using the Molecular Signatures
Database (MSigDB) to define KEGG pathways that were
specifically affected (Figure 3B). Interestingly, several sig-
naling pathways were identified, including the presence
of a T-cell receptor signaling signature in early B-cells of
Btg1–/–;Btg2–/– mice showing upregulation of Cd3d
(Cd3delta) and Cd3g (Cd3gamma) (Online Supplementary
Table S1). Therefore, we aimed to assess whether
Btg1;Btg2-deficient progenitor B-cells displayed aberrant
expression of other T-lineage specific genes, including
Cd4, Ikzf2, Tcf7, Gata3 and Notch1. Indeed, qRT-PCR
revealed that Btg1–/–;Btg2–/– B220+ BM cells showed signif-
icantly increased expression levels of these T-lineage
marker genes (Figure 3C), while we also observed higher
expression of the CD3, CD4 and CD8 cell surface mark-
ers on Btg1–/–;Btg2–/– committed B-cells (Online
Supplementary Figure S6). These findings suggest that Btg1
and Btg2 are implicated in regulating B-lineage commit-
ment by suppressing the expression of lineage-inappro-
priate genes. 
In summary, using genetic mouse models, we demon-
strate that both Btg1 and Btg2 promote mouse B-cell dif-
ferentiation at multiple stages of development, and most-
ly display overlapping functions during B lymphopoiesis,
which corresponds with an additive phenotype in the
Btg1–/–;Btg2–/– mice. On the other hand, Btg1 fulfills a more
prominent role in promoting the proliferative expansion
of lymphoid progenitors by inhibiting apoptosis. This is
in agreement with the finding that Btg1 ablation in the
mouse brain decreases the pool of proliferating stem and
progenitor cells, which is accompanied by increased
apoptosis.12 Importantly, Btg1 and Btg2 are both required
to repress T-lineage gene expression in progenitor B-cells.
These findings are partially overlapping with the pheno-
type observed in Ebf1 and Pax5 knockout mice, where it
has been shown that EBF1 and PAX5 are critical regula-
tors of B-lineage specification and commitment by
repressing alternative non-B-cell fates.13-15 As the expres-
sion of Ebf1 and Pax5 itself is not inhibited in
Btg1–/–;Btg2–/– progenitor B-cells, the BTG1 and BTG2 tran-
scriptional coregulators may affect B-lineage commit-
ment by modifying the function of these B-cell specific
transcription factors or by epigenetic regulation of their
target genes. Notably, PAX5 and EBF1, similar to BTG1,
are also subject to gene deletions in BCP-ALL, and com-
binations of these deletions often co-occur in the same
leukemia.4 Together our findings suggest that the block in
differentiation observed in BCP-ALL may result from
gene alterations affecting multiple master regulators of B-
cell differentiation.        
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